Does combined treatment with dexamethasone and raloxifene totally abrogate osteoporosis and joint destruction in experimental postmenopausal arthritis?
Addition of raloxifene or estradiol to dexamethasone-treatment in experimental postmenopausal polyarthritis prevents generalized bone loss.
Our results suggest that the PvuII polymorphism may play an important role in determining ETV efficacy after 48 and 96 weeks of treatment, at least in this study population.